EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lytix Biopharma AS's EBITDA for the
three
months ended in Mar. 2026 was €-2.38 Mil. Lytix Biopharma AS's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, Lytix Biopharma AS's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
Lytix Biopharma AS (STU:6BG) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Lytix Biopharma AS EBITDA Margin % Related Terms
Lytix Biopharma AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Lytix Biopharma AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6BG vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Lytix Biopharma AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lytix Biopharma AS EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lytix Biopharma AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Lytix Biopharma AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lytix Biopharma AS (STU:6BG) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lytix Biopharma AS and its competitors. According to the industry distribution chart, Lytix Biopharma AS ranks #999999 out of 936 companies in the Biotechnology industry.
Is Lytix Biopharma AS's EBITDA Margin % too high?
Lytix Biopharma AS's current EBITDA Margin % is 0.00%. Based on the distribution chart, Lytix Biopharma AS ranks #999999 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lytix Biopharma AS has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lytix Biopharma AS ranks #999999 out of 936 companies for EBITDA Margin %. This places Lytix Biopharma AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lytix Biopharma AS and its competitors. Lytix Biopharma AS's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Lytix Biopharma AS (STU:6BG) has a current EBITDA Margin % of 0.00%. The stock's GF Value™ is €0.01, compared to a current price of €0.80 — trading 7940% above its estimated fair value. The current EBITDA Margin % is 0.00%. Lytix Biopharma AS's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lytix Biopharma AS (STU:6BG), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lytix Biopharma AS (STU:6BG) Overvalued in 2026?
Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued.
The current stock price of €0.80 is trading 7940% above its estimated GF Value™ of €0.01.
Key valuation signals for STU:6BG:
EBITDA Margin %: 0.00%
GF Value™: €0.01 vs. price of €0.80 (7940% above fair value)
No single metric tells the full story. See the STU:6BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
30GF Score
Get the complete analysis for STU:6BG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6BG has been successfully added to your 
